The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

The product, an oral RET inhibitor, was approved in 2020 by the FDA to treat adults with metastatic RET fusion-positive non-small-cell lung cancer (NSCLC), shortly after Roche paid $775 million ...

[31] XL-184 (BMS 907351, cabozantinib; Exelixis, South San Francisco, CA, USA) is an oral inhibitor of several TK receptors. The primary targets are VEGFR2, RET, c-KIT and MET, which is highly ...